We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Immunoassays Evaluated for Thyroid-Stimulating Receptor Antibody in Graves’ Disease

By LabMedica International staff writers
Posted on 23 Nov 2021
Print article
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)
Image: The IMMULITE 2000 XPi Immunoassay System provides multiple tests on a single, easy-to-use analyzer, including the thyroid-stimulating immunoglobulin assay (Photo courtesy of Siemens Healthcare)
Graves' disease (GD), also known as toxic diffuse goiter, is an autoimmune disease that affects the thyroid. It frequently results in and is the most common cause of hyperthyroidism and it also often results in an enlarged thyroid.

Thyroid-stimulating hormone (TSH) receptor (TSHR) autoantibodies (TRAbs) are pathognomonic of GD and are detected in the serum of approximately 98% of patients with untreated GD. The specific and sensitive detection of thyroid-stimulating immunoglobulin (TSI) from other types of TRAbs is becoming increasingly important for the diagnostic accuracy of the Graves’ hyperthyroidism and of the extrathyroidal manifestations of GD.

Medical Laboratorians at the Shanghai Medical College (Shanghai, China) and their colleagues recruited 559 patients in the period between October 2020 and February 2021. There were 166 GD patients, 81 patients of whom were untreated GD, 393 patients with other thyroid diseases including 79 patients with Hashimoto's thyroiditis, 103 patients with thyroid nodules, 96 patients with hypothyroidism, 59 patients with nontoxic goiter, and 56 patients with thyroid cyst. In addition, 20 euthyroid healthy subjects were recruited as normal controls.

The team evaluated the analytical and clinical performance of two immunoassays for diagnosis of Graves’ disease (GD): the Immulite thyroid-stimulating immunoglobulin (TSI, Siemens Healthcare, Erlangen, Germany), and the Elecsys Anti-TSH receptor (TSHR), assay (Roche Diagnostics, Mannheim, Germany). The Immulite TSI assay is a chemiluminescence immunoassay with the clinical decision point of 0.55 IU/L. The Roche Elecsys Anti-TSHR assay is a competitive assay using electrochemiluminescence detection.

The investigators reported that the repeatability and intermediate imprecision coefficient of variation (CV%) of the TSI assay were 3.8% and 4.1% at 0.95 IU/L, and 3.5% and 3.6% at 19.5 IU/L, respectively. The assays were linear over a range 0.27–38.5 IU/L. There was a high correlation between the quantitative results of the two methods. The cut-off value obtained by ROC analysis for TSI assay was 0.7 IU/L with sensitivity of 93.7% and specificity of 85.1%. An overall qualitative agreement of 91.5% between two methods was observed. Among 44 patients with discordant qualitative results, the TSI assay provided more satisfactory results consistent with clinical diagnoses.

The authors concluded that the Immulite TSI assay specifically measured the pathogenic antibody of GD and exhibited excellent analytical performance. The Immulite TSI assay may be of great value for the clinical diagnosis of GD. The study was published on November 11, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Shanghai Medical College
Siemens Healthcare
Roche Diagnostics

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
POC Test Reader
High-Throughput Cellular Screening System
Microbial Infections In-Vitro Diagnostic Solution
Weezion dx

Print article


Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.